Appendix 3 Risk of Bias assessment for outcomes of includ	ed RCTs
---	---------

Outcomes of Trials	Sequence generation	Allocation concealment	Blinding (patients)	Blinding	Blinding (outcome assessors)	Blinding (data collectors)	Blinding (data analyst)	Loss to follow-up
				(health care providers)				
Death	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
ESKD	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Remission	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Serious adverse	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
events	Low	Low	Low	Low	Low	Low	Low	Low
Serious infections	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Health-related quality	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
of life	Low	Low	Low	Low	Low	Low	Low	Low
Furuta et al. 2021								
Death	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
ESKD	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Remission	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Relapse	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Serious adverse	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
events	Low	Low	Low	Low	Low	Low	Low	Low
Serious infections	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
	Low	Low	Low	Low	Low	Low	Low	Low
Health-related quality	Definitely	Definitely	Probably	Probably	Probably	Probably	Probably	Definitely
of life	Low	Low	Low	Low	Low	Low	Low	Low

ESKD: end-stage kidney disease; RCT: randomized controlled trial.